-
cahps.ahrq.gov/news/newsletters/e-newsletter/811.html
April 01, 2022 - stimulant and opioid co-use, such as the Addictions, Drug & Alcohol Institute’s People Who Use Opioids and Stimulants
-
monahrq.ahrq.gov/news/newsletters/e-newsletter/811.html
April 01, 2022 - stimulant and opioid co-use, such as the Addictions, Drug & Alcohol Institute’s People Who Use Opioids and Stimulants
-
teamstepps.ahrq.gov/news/newsletters/e-newsletter/811.html
April 01, 2022 - stimulant and opioid co-use, such as the Addictions, Drug & Alcohol Institute’s People Who Use Opioids and Stimulants
-
ce.effectivehealthcare.ahrq.gov/news/newsletters/e-newsletter/811.html
April 01, 2022 - stimulant and opioid co-use, such as the Addictions, Drug & Alcohol Institute’s People Who Use Opioids and Stimulants
-
meps.ahrq.gov/data_files/publications/st277/draft/stat277.shtml
January 01, 2010 - In 1997, within the gastrointestinal agents therapeutic class, GI stimulants was a first choice therapeutic … In 2007, GI stimulants was not a first choice therapeutic subclass for the MEPS data.
-
meps.ahrq.gov/data_files/publications/st277/sb277.xml.bak
January 01, 2010 - In 1997, within the gastrointestinal agents therapeutic class, GI stimulants was a first choice therapeutic … In 2007, GI stimulants was not a first choice therapeutic subclass for the MEPS data.
-
meps.ahrq.gov/data_files/publications/st277/sb277.xml
January 01, 2010 - In 1997, within the gastrointestinal agents therapeutic class, GI stimulants was a first choice therapeutic … In 2007, GI stimulants was not a first choice therapeutic subclass for the MEPS data.
-
meps.ahrq.gov/data_files/publications/st277/stat277.shtml.bak
January 01, 2010 - In 1997, within the gastrointestinal agents therapeutic class, GI stimulants was a first choice therapeutic … In 2007, GI stimulants was not a first choice therapeutic subclass for the MEPS data.
-
meps.ahrq.gov/data_files/publications/st277/stat277.pdf
January 01, 2010 - In 1997, within the
gastrointestinal agents therapeutic class, GI stimulants was a first choice therapeutic … In 2007, GI stimulants was not a first choice therapeutic subclass for the MEPS data.
-
meps.ahrq.gov/data_files/publications/st277/stat277.shtml
January 01, 2010 - In 1997, within the gastrointestinal agents therapeutic class, GI stimulants was a first choice therapeutic … In 2007, GI stimulants was not a first choice therapeutic subclass for the MEPS data.
-
srdr.ahrq.gov/projects/592/studies/81947
January 01, 1997 - Select a Topic:
User Home Screen
Extraction Forms
Project Creation
Study Creation
Preview Pages
Other
Your Feedback:
Submit
Reset
Cancel
Study Preview
Study Title and Description
Combined neuromuscular electrical stimulation and …
-
hcup-us.ahrq.gov/reports/statbriefs/sb216-appendix.pdf
October 01, 2004 - similar cases.)
967.0 Poisoning – analeptics
970.81
Poisoning – other central nervous system stimulants … E854.2 Accidental poisoning by psychostimulants
E854.3 Accidental poisoning by central nervous system stimulants … antagonists causing adverse effects in therapeutic use
E940.8 Other specified central nervous system stimulants
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/disruptive-behavior-disorder_research-protocol.pdf
January 30, 2014 - stabilizers, anticonvulsants, and psychostimulants.42 Combination
therapy with antipsychotics and stimulants … for disruptive behaviors, are
alpha-agonists, anticonvulsants, beta-blockers, central nervous system stimulants … antipsychotics, beta-adrenergic
blocking agents (i.e., beta-blockers), central nervous system (CNS) stimulants … serotonin
reuptake inhibitors"[tiab] OR "Serotonin Uptake Inhibitors" [Pharmacological Action]
OR stimulants … [tiab] OR "Central Nervous System Stimulants"[Mesh] OR "Central
Nervous System Stimulants" [Pharmacological
-
pbrn.ahrq.gov/news/newsletters/e-newsletter/866.html
May 01, 2023 - Trends in dispensed prescriptions for opioids, sedatives, benzodiazepines, gabapentin, and stimulants
-
pcmh.ahrq.gov/news/newsletters/e-newsletter/866.html
May 01, 2023 - Trends in dispensed prescriptions for opioids, sedatives, benzodiazepines, gabapentin, and stimulants
-
www.cahps.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/chipra_1415-p011-1-ef_0.pdf
March 01, 2015 - Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and
antipsychotics
-
www.innovations.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/chipra_1415-p011-1-ef_0.pdf
March 01, 2015 - Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and
antipsychotics
-
www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/chipra_1415-p011-1-ef_0.pdf
March 01, 2015 - Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and
antipsychotics
-
www.monahrq.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/chipra_1415-p011-1-ef_0.pdf
March 01, 2015 - Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and
antipsychotics
-
www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/chipra_1415-p011-1-ef_0.pdf
March 01, 2015 - Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and
antipsychotics